Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
Icosavax’s $209.3 Million IPO
Erasca’s $345 Million Initial Public Offering
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
Zentalis Pharmaceuticals’ $150.4 Million Common Stock Offering
Latham & Watkins LLP represented Zentalis Pharmaceuticals in the offering. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...
eFFECTOR Therapeutics’ Merger with Locust Walk Acquisition Corp.
Latham & Watkins LLP represented eFFECTOR in the transaction, eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors...
Icosavax’s $100 Million Series B Financing
Latham & Watkins LLP represented Icosavax, Inc. in the transaction. Icosavax, Inc. closed a US$100 million Series B Financing, led by RA Capital Management and joined by...
Mineralys Therapeutics’ $40 Million Series A Funding Round
Latham & Watkins LLP represented Mineralys Therapeutics, Inc. in the transaction. Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific, completed a US$40...
Longboard Pharmaceuticals’ $80.0 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. Longboard Pharmaceuticals, Inc. closed its initial public offering of 5 million shares of its common stock at...